Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-06-12 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and contains specific sections detailing an 'acquisition or disposal of voting rights' by 'The Goldman Sachs Group, Inc.' concerning 'Dechra Pharmaceuticals PLC'. It reports the resulting total positions in terms of voting rights percentages and numbers, referencing DTR rules (DTR5.1, DTR5.2.1, DTR5.3.1R). This structure is characteristic of a regulatory filing notifying a change in significant share ownership, which corresponds to the Major Shareholding Notification category (MRQ). Although it is a regulatory notification, MRQ is more specific than the general RNS fallback.
2023-06-12 English
Rule 2.9 Announcement
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Rule 2.9 Announcement' under the 'City Code on Takeovers and Mergers (the "Code")'. This type of announcement is mandatory during a takeover period to confirm the total number of shares in issue. While it relates to potential M&A activity (TAR), the specific nature of this filing—a mandatory disclosure regarding share capital count under takeover rules—is a specialized regulatory announcement. Since it is a formal, required disclosure related to a potential takeover/merger process, it fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for a Rule 2.9 announcement, and it is not the M&A proposal itself (TAR) nor a general capital change (SHA). Given the context of RNS Number and the standard regulatory boilerplate at the end, RNS is the most appropriate general regulatory classification for this specific, non-core report filing.
2023-06-09 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a mandatory disclosure required under UK takeover regulations when a party involved in a takeover (offeror or offeree) acquires or deals in relevant securities. This type of filing relates to insider transactions or significant ownership changes during a takeover scenario. While it involves director/insider activity (similar to DIRS), the specific context of the Takeover Code (Rule 8.3) and its relation to an ongoing offer (Dechra Pharmaceuticals plc) makes it a specialized disclosure. Since there is no specific code for 'Takeover Disclosure' or 'Insider Dealing during a Takeover', we must select the closest fit. Director's Dealing (DIRS) covers personal share transactions by directors/executives. Although the discloser here is Millennium International Management LP (an investment manager) and not strictly a director, the core function is reporting significant security interests and dealings related to a corporate event (the takeover context). However, given the options, this filing is most closely related to reporting ownership changes and transactions by interested parties, which aligns best with the spirit of insider/significant shareholder reporting. Since it is a specific regulatory disclosure related to ownership/dealing, and not a general regulatory announcement (RNS), DIRS is the most appropriate category among the choices, as it captures the essence of reporting personal/controlled security transactions by influential parties, even if the specific form (Form 8.3) is not explicitly listed. If 'Takeover Filing' were an option, it would be preferred. Given the constraints, DIRS is the closest fit for reporting significant security interests/dealings by an involved party.
2023-06-09 English
Form 8.3 - Dechra Pharmaceuticals Plc
Regulatory Filings Classification · 95% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals Plc" and contains the header "PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)". This form relates to disclosures required under the UK Takeover Code, typically during an offer period, detailing a person's interest or dealing in the relevant securities of an offeror or offeree. This type of disclosure, concerning insider dealings or major holdings during a takeover scenario, is not explicitly covered by the provided definitions (like 10-K, ER, or DIV). However, it is a specific regulatory filing related to insider transactions during a corporate action (takeover). Since it details personal share transactions by an entity (Farallon Capital Europe LLP) in relation to an offeree (Dechra Pharmaceuticals PLC) during a potential takeover scenario, it most closely aligns with the concept of insider dealing disclosure, which is similar in nature to Director's Dealing (DIRS), although this specific form (Form 8.3) is unique to takeover regulation. Given the options, and recognizing that this is a mandatory disclosure of interests/dealings by a significant shareholder during a takeover context, it is best classified as a specialized form of insider transaction reporting. Since there is no specific code for Takeover Code Disclosures (like Form 8.3), and it involves reporting dealings by an interested party, it falls under the general category of regulatory filings that report transactions, which is closest to DIRS (Director's Dealing) in spirit, but since it is a specific regulatory form not covered, the fallback category 'RNS' (Regulatory Filings) is the most appropriate general classification for mandatory, non-standard regulatory disclosures.
2023-06-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is distributed via 'RNS Number'. This form is used to report changes in significant share ownership thresholds. This directly corresponds to the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific to a major holding change, making MRQ the most precise classification over the general RNS fallback.
2023-06-09 English
Form 8.3 - Dechra Pharmaceuticals plc
M&A Activity Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of disclosure relates to insider trading or significant ownership changes during a M&A event, but the specific form (Form 8.3) is a regulatory filing related to takeover activity. While it involves share dealings, it is distinct from standard Director's Dealing (DIRS) which usually refers to Form 3/4/5 filings under securities law, not the Takeover Code. Since the document details dealings and positions related to an ongoing takeover scenario, it falls under the scope of M&A Activity (TAR) or potentially a specific regulatory filing. Given the options, 'TAR' (M&A Activity) is the most relevant category as Form 8.3 is intrinsically linked to a takeover bid. If TAR was not available, RNS would be the fallback, but TAR captures the context better.
2023-06-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.